Laniquidar
Laniquidar
Laniquidar (pronounced: lan-qui-dar) is a pharmaceutical drug used in the field of medicine and pharmacology. It is a potent and selective inhibitor of the P-glycoprotein (P-gp) efflux pump, which is known to contribute to multidrug resistance in cancer treatment.
Etymology
The term "Laniquidar" is derived from the Latin words 'lan' meaning wool and 'quidar' meaning to care. This is a metaphorical representation of the drug's function, which is to 'care' for the 'wool' or the complex network of cells in the body.
Usage
Laniquidar is primarily used in the treatment of cancer, specifically in cases where the cancer has developed resistance to multiple drugs. By inhibiting the P-glycoprotein efflux pump, Laniquidar allows for more effective absorption of chemotherapy drugs into the cancer cells, thereby enhancing the efficacy of the treatment.
Related Terms
- P-glycoprotein: A protein that pumps foreign substances out of cells. Overexpression of P-glycoprotein can lead to multidrug resistance in cancer cells.
- Multidrug resistance: A condition where cancer cells become resistant to a wide range of drugs, making treatment more difficult.
- Pharmacology: The branch of medicine concerned with the uses, effects, and modes of action of drugs.
- Chemotherapy: A type of cancer treatment that uses drugs to kill cancer cells.
See Also
External links
- Medical encyclopedia article on Laniquidar
- Wikipedia's article - Laniquidar
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski